This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review


18 January, 2017  

Boehringer Ingelheim has announced that BI 695501, its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and FDA.